The estimated Net Worth of Daniel R. Chevallard is at least $141 ezer dollars as of 1 July 2019. Daniel Chevallard owns over 2,669 units of Regulus Therapeutics Inc stock worth over $119,920 and over the last 8 years Daniel sold RGLS stock worth over $20,784.
Daniel has made over 4 trades of the Regulus Therapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently Daniel sold 2,669 units of RGLS stock worth $3,496 on 1 July 2019.
The largest trade Daniel's ever made was buying 54,945 units of Regulus Therapeutics Inc stock on 25 July 2017 worth over $50,000. On average, Daniel trades about 8,858 units every 88 days since 2017. As of 1 July 2019 Daniel still owns at least 77,870 units of Regulus Therapeutics Inc stock.
You can see the complete history of Daniel Chevallard stock trades at the bottom of the page.
Daniel's mailing address filed with the SEC is C/O REGULUS THERAPEUTICS INC., 10628 SCIENCE CENTER DR., #225, SAN DIEGO, CA, 92121.
Over the last 12 years, insiders at Regulus Therapeutics Inc have traded over $78,282,075 worth of Regulus Therapeutics Inc stock and bought 65,288,007 units worth $66,275,578 . The most active insiders traders include Forest Baskett, Scott D Sandell és Anthony A. Jr. Florence. On average, Regulus Therapeutics Inc executives and independent directors trade stock every 34 days with the average trade being worth of $890,488. The most recent stock trade was executed by Kathryn J Collier on 25 July 2024, trading 4,000 units of RGLS stock currently worth $7,280.
regulus therapeutics inc. (nasdaq:rgls) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting micrornas. regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microrna therapeutics pipeline complemented by a maturing micromarkerssm biomarkers platform and a rich intellectual property estate to retain its leadership in the microrna field. regulus is developing rg-101, a galnac-conjugated anti-mir targeting microrna-122 for the treatment of chronic hepatitis c virus infection, and rg-012, an anti-mir targeting microrna-21 for the treatment of alport syndrome, a life-threatening kidney disease driven by genetic mutations with no approved therapy. in addition, rg-125, a galnac-conjugated anti-mir targeting microrna-103/107 for the treatment of nash in patients with type 2 diabetes/pre-diabetes, has entered phase i clinical development through its strategic alliance with astrazeneca. reg
Regulus Therapeutics Inc executives and other stock owners filed with the SEC include: